Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -3-
July 9, 2001
- CDFS Committee to Draft GL for Package Inserts for Medical Devices
July 9, 2001
- BUSINESS NEWS IN BRIEF -2-
July 9, 2001
- WORLD NEWS IN BRIEF
July 9, 2001
- BUSINESS NEWS IN BRIEF -1-
July 9, 2001
- Pharmacia Enhances R&D Organization in Japan
July 9, 2001
- Shareholders' Meetings Last Longer Due to Increasing Number of Questions
July 9, 2001
- Superiority of Singulaire over Pranlukast Verified: Banyu Symposium
July 9, 2001
- Gap Between NHI Prices and Market Prices Widening to about 7%
July 9, 2001
- Package Insert Drafting Guidebook for Medical Devices Issued
July 9, 2001
- Kasamatsu Meiki, Hokuho Iyaku Tie Up in Hokuriku
July 9, 2001
- Fresenius Medical Care to Become Major Player in Japan: President van Hest
July 2, 2001
- Physicians Should Also Be Forbidden to Receive Gifts: Maker FTC
July 2, 2001
- REGULATORY NEWS IN BRIEF
July 2, 2001
- Bayer AG to Increase Share in Asia-Pacific from 16% to 25%
July 2, 2001
- Japan Is Lagging Behind the US in Life Science: S&T White Paper
July 2, 2001
- M&A, Alliance Effective for Strengthening R&D Ability: EAD Director
July 2, 2001
- CORPORATE ROUNDUP
July 2, 2001
- Aventis Aiming to Achieve Highest Growth Rate in Japan: President Loescher
July 2, 2001
- Council for Regulatory Reform to Focus on Medical Fees, NHI Prices
July 2, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…